Other languages Lumos Pharma, Inc.

Equities

LUMO

US55028X1090

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
2.25 ^USD	-1.75%		-8.20%	-29.25%

May. 15	Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA	CI
May. 15	Lumos Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024	May. 20
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA	May. 15
Lumos Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 15
Transcript : Lumos Pharma, Inc., Q1 2024 Earnings Call, May 15, 2024	May. 15
Lumos Pharma Plans Phase 3 Study of Growth Hormone Drug	May. 14
Lumos: Q1 Earnings Snapshot	May. 14
Earnings Flash (LUMO) LUMOS PHARMA Posts Q1 Revenue $165,000, vs. Street Est of $0.3M	May. 14
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results	May. 14
Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024	May. 09
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings	Apr. 18
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042	Mar. 20
Lumos Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 07
Transcript : Lumos Pharma, Inc., 2023 Earnings Call, Mar 07, 2024	Mar. 07
Earnings Flash (LUMO) LUMOS PHARMA Reports Q4 Revenue $2.1M	Mar. 07
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update	Mar. 07
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024	Feb. 26
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024	Feb. 26
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference	Feb. 05
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference	Feb. 05
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer	Jan. 04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Lumos Pharma, Inc.

Equities

LUMO

US55028X1090

Other languages

Filters